<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FURAZOLIDONE</span><br/>(fur-a-zoe'li-done)<br/><span class="topboxtradename">Furoxone<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">nitrofuran antibiotic</span>; <span class="classification">mao inhibitor</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg tablets; 50 mg/15 mL liquid</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic nitrofuran with antibacterial and antiprotozoal properties. Acts by interfering with several bacterial enzyme systems
         including cell wall synthesis of the bacteria.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>A <small>MAO INHIBITOR</small> that is cumulative and dose related (occurring after 4 or 5 d of therapy). Bactericidal against majority of GI pathogens,
         including species of <i>Enterobacter aerogenes, Escherichia coli, Giardia lamblia, Proteus, Salmonella, Shigella, Staphylococcus,</i> and <i>Vibrio cholerae</i>.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Bacterial or protozoal diarrhea and enteritis caused by susceptible organisms.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to furazolidone, concurrent use with alcohol, other <small>MAO INHIBITOR</small>, tyramine-containing foods, indirect-acting sympathomimetic amines; infants 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>If at all, patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Diarrhea and Enteritis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100 mg q.i.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 1 mo1 y, 817 mg q.i.d.; 14 y, 1725 mg q.i.d.; <img src="../images/special/greaterorequal.gif"/>5 y,
               2550 mg q.i.d. (max: 8.8 mg/kg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Store in tight, light-resistant containers (drug darkens on exposure to light). Protect from excessive heat.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">GI:</span> <span class="speceff-common">Nausea, vomiting,</span> abdominal pain, diarrhea. <span class="typehead">Hypersensitivity:</span> Fever, arthralgia, hypotension, urticaria, angioedema, vesicular or morbilliform rash. <span class="typehead">Body as a Whole:</span> Headache, malaise, dizziness, hypoglycemia. <span class="typehead">Hematologic:</span> Intravascular hemolysis in patients with G6PD deficiency, <span class="speceff-life">agranulocytosis (rare)</span>. <span class="typehead">Special Senses:</span> Partial deafness. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Furazolidone metabolite reportedly may cause false-positive reactions for <span class="alt">urine glucose</span> with <span class="alt">copper sulfate reduction methods,</span> e.g., <span class="alt">Benedict's reagent,</span> <span class="alt">Clinitest,</span> and <span class="alt">Fehling's solution.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span> <b>Alcohol</b> may elicit disulfiram-type reaction up to 4 d after the drug is stopped; <span class="classification">mao inhibitors</span>, <span class="classification">narcotics</span>, <span class="classification">sympathomimetic amines</span>, <b>ephedrine</b>, <b>phenylpropanolamine</b> may cause a hypertensive reaction; <span class="classification">tricyclic antidepressants</span> may cause toxic psychosis. <span class="typehead">Food:</span> may interact with tyramine-containing foods, resulting in flushing, tachycardia, and hypertensive crisis. See <b>phenelzine</b> (<span class="classification">mao inhibitor</span> prototype). <span class="typehead">Herbal:</span> <b>Ginseng</b> may cause hypertension, manic symptoms, headaches, nervousness; <b>ma-huang,</b> <b>ephedra,</b> <b>St. John's wort</b> may lead to hypertensive crisis. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Poorly absorbed from GI tract. <span class="typehead">Metabolism:</span> Metabolized in intestines. <span class="typehead">Elimination:</span> Excreted in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for nausea and vomiting. Dosage reduction may be needed.</li>
<li> 							Note: Bed rest, fluid and electrolyte replacement (as indicated) are important adjuncts to therapy. Consult physician regarding
            dietary allowances. 						
         </li>
<li>Keep physician informed of S&amp;S of dehydration (see Appendix F) and electrolyte imbalance.</li>
<li>Monitor patients for lost glycemic control because drug may cause hypoglycemia (see Appendix F). Use glucose oxidase methods
            for urine testing (e.g., Clinistix, Diastix, TesTape).
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report the following to physician: Faintness, weakness, and light-headedness. These may be symptoms of hypersensitivity reaction
            or hypoglycemia.
         </li>
<li>Be aware of and avoid foods high in tyramine (e.g., aged and fermented food and drinks) that may produce hypertensive reaction.
            Hypertensive crisis is most likely to occur when drug is continued beyond 5 d or when large doses are given.
         </li>
<li>Do not drink alcohol during furazolidone therapy and for at least 4 d after drug is stopped. Ingestion of alcohol may cause
            disulfiram-type reaction (see Appendix F); symptoms may last up to 24 h.
         </li>
<li> 							Note: Drug may impart a harmless brown color to urine. 						</li>
<li>Monitor blood glucose for loss of glucemic control if diabetic.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>